Healthcare & Life Science

After record highs in 2021, recent reports show a global pullback in venture capital funding with a 33 percent drop from Q2 to Q3 2022. However, as founders prepare to weather a tougher fundraising environment, there is still some positive news. Nationally, dry powder, which is the amount of capital…

As businesses prepare for the rollout of new state privacy laws and the update to California’s comprehensive consumer privacy law that will all take effect in 2023, KO’s data privacy and security team recently launched a four-part educational video series to help businesses prepare to operate under the evolving patchwork…

KO client Watchmaker Genomics, a life sciences company specializing in the development of high-stringency applications focused on the reading, writing and editing of DNA and RNA, has raised $40M to expand its clinical sequencing product offerings.   The KO team, led by partner Jon Taylor, of counsel Melissa Mellen and attorney…

KO client Clinimark, a global leader for clinical FDA validation testing of vital sign data for medical and home health devices, has been acquired by Element Materials Technology. The KO team, led by attorney Ryan Sykora, partner John Gaddis, attorney Logan DeSouza and corporate paralegal Sara Shelly, represented Clinimark in…

KO client Highline Sciences, a specialized, full-service clinical contract research organization (CRO) focused on oncology, has been acquired by Tempus. The KO team, led by attorneys Samantha Pjesky, Jon Taylor and Ryan Ivey, represented Highline in this acquisition. Tempus is a leader in artificial intelligence and precision medicine. With this…

KO Client Plato BioPharma, Inc., a Colorado-based pharmacology research and drug discovery company, has been acquired by leading contract research organization Inotiv, Inc. The KO team, led by partner John Gaddis, represented Plato BioPharma in the acquisition. Plato BioPharma specializes in cardiovascular, renal, pulmonary and hepatic therapeutic areas, specifically within…

Sydnexis, Inc., a clinical stage biopharmaceutical company, has completed a $45 million Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund. The KO team, led by partners Kevin Gibson and Brad Schoenfeld, represented Sydnexis. The company sees progressive myopia (nearsightedness) in children as a “significant…

VitriVax, the developer of a novel stabilization and delivery platform for vaccines and therapeutics, has closed its first institutional financing round with Adjuvant Capital. KO partners Jon Taylor and Brad Schoenfeld, and attorney Matt Burns represented VitriVax in the financing round. The Series A proceeds will be used to develop…